Dysbindin Domain-Containing 1 in Prostate Cancer: New Insights into Bioinformatic Validation of Molecular and Immunological Features.

DBNDD1 gene expression E2F GSK-3β bioinformatic investigation cell cycle dysbindin protein family genes immunology microtubule cytoskeleton prostate cancer tumor-infiltrating immune cell

Journal

International journal of molecular sciences
ISSN: 1422-0067
Titre abrégé: Int J Mol Sci
Pays: Switzerland
ID NLM: 101092791

Informations de publication

Date de publication:
25 Jul 2023
Historique:
received: 14 06 2023
revised: 17 07 2023
accepted: 19 07 2023
medline: 12 8 2023
pubmed: 12 8 2023
entrez: 12 8 2023
Statut: epublish

Résumé

Prostate cancer (PCa) is one of the most prevalent cancers in men, yet its pathogenic pathways remain poorly understood. Transcriptomics and high-throughput sequencing can help uncover cancer diagnostic targets and understand biological circuits. Using prostate adenocarcinoma (PRAD) datasets of various web-based applications (GEPIA, UALCAN, cBioPortal, SR Plot, hTFtarget, Genome Browser, and MetaCore), we found that upregulated dysbindin domain-containing 1 (

Identifiants

pubmed: 37569304
pii: ijms241511930
doi: 10.3390/ijms241511930
pmc: PMC10418609
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Subventions

Organisme : 1. National Science and Technology Council, Taiwan 2. National Health Research Institutes, Taiwan 3. TMU Research Center of Cancer Translational Medicine
ID : 1. MOST109-2326-B-038-001-MY3 2. MOST111-2628-B-038-016-MY3

Références

J Microbiol Immunol Infect. 2021 Oct;54(5):845-857
pubmed: 34176764
Biomedicines. 2021 Nov 30;9(12):
pubmed: 34944621
Nucleic Acids Res. 2000 Jan 1;28(1):27-30
pubmed: 10592173
Prostate Cancer Prostatic Dis. 2014 Sep;17(3):220-6
pubmed: 24796290
Nat Rev Mol Cell Biol. 2001 Oct;2(10):769-76
pubmed: 11584304
Nature. 2018 Jul;559(7714):363-369
pubmed: 29950727
Adv Immunol. 2007;96:179-204
pubmed: 17981207
J Mol Cell Biol. 2017 Dec 1;9(6):504-515
pubmed: 29040676
Front Pharmacol. 2021 Sep 23;12:738235
pubmed: 34630112
Cancer Cell. 2005 May;7(5):411-23
pubmed: 15894262
Front Oncol. 2020 Oct 29;10:517637
pubmed: 33194581
Front Immunol. 2020 Jul 30;11:1680
pubmed: 32849585
Psychooncology. 2013 Oct;22(10):2169-76
pubmed: 23483679
Nat Med. 2016 Apr;22(4):369-78
pubmed: 26928463
Nucleic Acids Res. 2017 Jul 3;45(W1):W98-W102
pubmed: 28407145
Eur J Pharmacol. 2020 Jun 15;877:173090
pubmed: 32234529
Nucleic Acids Res. 2014 Jan;42(Database issue):D472-7
pubmed: 24243840
Sci Rep. 2019 Nov 8;9(1):16359
pubmed: 31704974
Cell. 1997 Feb 7;88(3):323-31
pubmed: 9039259
J Pers Med. 2021 Oct 26;11(11):
pubmed: 34834441
Cancer Res. 2017 Nov 1;77(21):e108-e110
pubmed: 29092952
Urol Oncol. 2015 Nov;33(11):456-63
pubmed: 26051358
Mod Pathol. 2018 Jan;31(S1):S110-121
pubmed: 29297495
Am J Clin Exp Urol. 2022 Aug 15;10(4):210-233
pubmed: 36051616
Nucleic Acids Res. 2012 Jan;40(Database issue):D1301-7
pubmed: 22096230
BMC Cancer. 2021 Mar 16;21(1):286
pubmed: 33726701
Nat Rev Cancer. 2001 Nov;1(2):109-17
pubmed: 11905802
BMC Genomics. 2015 Oct 28;16:873
pubmed: 26510534
Schizophr Res. 2003 Apr 1;60(2-3):167-72
pubmed: 12591580
Nat Commun. 2023 Mar 30;14(1):1787
pubmed: 36997534
Nat Cancer. 2021 Aug;2(8):803-818
pubmed: 35122025
Science. 1989 Nov 3;246(4930):629-34
pubmed: 2683079
Cell Death Dis. 2018 Oct 11;9(10):1041
pubmed: 30310055
Prostate. 2012 May 1;72(6):649-60
pubmed: 21837779
J Cancer. 2020 Feb 21;11(10):2821-2829
pubmed: 32226500
J Immunother Cancer. 2022 Mar;10(3):
pubmed: 35296557
Sci Rep. 2022 Jan 7;12(1):211
pubmed: 34997064
Cell. 2018 Apr 5;173(2):305-320.e10
pubmed: 29625049
Gene. 2019 Aug 20;710:333-340
pubmed: 31202904
Front Oncol. 2022 Aug 11;12:958756
pubmed: 36033455
Cancers (Basel). 2021 Sep 29;13(19):
pubmed: 34638387
Anticancer Res. 2009 Jun;29(6):2077-81
pubmed: 19528467
Front Surg. 2022 Mar 17;9:856446
pubmed: 35372462
Cancer Lett. 2022 Jan 28;525:9-21
pubmed: 34715253
Int J Mol Sci. 2021 Mar 05;22(5):
pubmed: 33807717
Nat Genet. 2000 May;25(1):25-9
pubmed: 10802651
Nat Biotechnol. 2020 Jun;38(6):675-678
pubmed: 32444850
Aging (Albany NY). 2021 Jul 30;13(14):17970
pubmed: 34329194
Mol Psychiatry. 2010 Oct;15(10):969
pubmed: 20861847
Cancer Lett. 2020 May 1;477:107-121
pubmed: 32120026
Aging (Albany NY). 2022 Oct 30;14(20):8498-8567
pubmed: 36315446
Neoplasia. 2017 Aug;19(8):649-658
pubmed: 28732212
EMBO Mol Med. 2014 May 01;6(5):651-61
pubmed: 24737870
Int J Oncol. 2016 Apr;48(4):1650-8
pubmed: 26891801
Genomics Proteomics Bioinformatics. 2020 Apr;18(2):120-128
pubmed: 32858223
Nucleic Acids Res. 2013 Jan;41(Database issue):D991-5
pubmed: 23193258
Methods Mol Biol. 2007;395:17-34
pubmed: 17993665
Cells. 2020 Jul 08;9(7):
pubmed: 32650578
Oncol Rep. 2020 Sep;44(3):849-862
pubmed: 32582990
Schizophr Bull. 2005 Oct;31(4):800-5
pubmed: 16166606
Nucleic Acids Res. 2022 Jul 5;50(W1):W367-W374
pubmed: 35609980
Cancer Lett. 2016 May 28;375(1):152-161
pubmed: 26968249
J Cell Physiol. 2016 Nov;231(11):2482-92
pubmed: 26919443
Am J Hum Genet. 2006 Nov;79(5):903-9
pubmed: 17033966
Diagnostics (Basel). 2019 Dec 11;9(4):
pubmed: 31835700
Oncogene. 2023 Mar;42(12):926-937
pubmed: 36725887
J Cell Physiol. 2020 Nov;235(11):8472-8485
pubmed: 32329523
Molecules. 2022 Sep 05;27(17):
pubmed: 36080493
Infect Genet Evol. 2020 Nov;85:104438
pubmed: 32615317
Nature. 2020 Mar;579(7800):567-574
pubmed: 32214244
Clin Cancer Res. 2009 Sep 15;15(18):5794-802
pubmed: 19737960
Nature. 2022 Sep;609(7927):S42-S44
pubmed: 36104410
Cancer Cell. 2005 Nov;8(5):393-406
pubmed: 16286247
J Immunol Res. 2022 Sep 1;2022:3883822
pubmed: 36093436
Cancers (Basel). 2021 Apr 18;13(8):
pubmed: 33919517
Nat Commun. 2023 Mar 22;14(1):1449
pubmed: 36949101
CA Cancer J Clin. 2023 Jan;73(1):17-48
pubmed: 36633525
J Clin Invest. 2018 Jan 2;128(1):341-358
pubmed: 29202480
Aging (Albany NY). 2021 Nov 28;13(22):24882-24913
pubmed: 34839279
Nature. 2010 Mar 11;464(7286):302-5
pubmed: 20220849
Am J Cancer Res. 2020 Jan 01;10(1):95-113
pubmed: 32064155
Proc Natl Acad Sci U S A. 2019 Oct 22;116(43):21704-21714
pubmed: 31591235
Pathology. 2019 Aug;51(5):463-473
pubmed: 31279442
Cancer Res. 2022 Jan 15;82(2):221-234
pubmed: 34625422
Prostate Cancer Prostatic Dis. 2009;12(3):233-40
pubmed: 19488067
J Exp Clin Cancer Res. 2023 Jan 14;42(1):22
pubmed: 36639681
Cancers (Basel). 2020 Jan 18;12(1):
pubmed: 31963677
Am J Cancer Res. 2021 Apr 15;11(4):1012-1030
pubmed: 33948343
Cells. 2020 Apr 28;9(5):
pubmed: 32354165
Int J Mol Sci. 2017 Sep 22;18(10):
pubmed: 28937620
Endocr Relat Cancer. 2020 Feb;27(2):R35-R50
pubmed: 31804971
EMBO J. 2004 Oct 27;23(21):4202-10
pubmed: 15470505
Cancer Inform. 2019 Mar 13;18:1176935119835522
pubmed: 30890858
Int J Mol Sci. 2022 Jan 12;23(2):
pubmed: 35054979
Cancers (Basel). 2023 Feb 01;15(3):
pubmed: 36765877

Auteurs

Van Thi Ngoc Tram (VTN)

International Ph.D. Program in Medicine, College of Medicine, Taipei Medical University, Taipei 110, Taiwan.
Department of Medical Laboratory, University Medical Center Ho Chi Minh City, Ho Chi Minh City 700000, Vietnam.

Hoang Dang Khoa Ta (HD)

Graduate Institute of Cancer Biology and Drug Discovery, College of Medical Science and Technology, Taipei Medical University, Taipei 110, Taiwan.
Ph.D. Program for Cancer Molecular Biology and Drug Discovery, College of Medical Science and Technology, Taipei Medical University and Academia Sinica, Taipei 110, Taiwan.

Gangga Anuraga (G)

Graduate Institute of Cancer Biology and Drug Discovery, College of Medical Science and Technology, Taipei Medical University, Taipei 110, Taiwan.
Ph.D. Program for Cancer Molecular Biology and Drug Discovery, College of Medical Science and Technology, Taipei Medical University and Academia Sinica, Taipei 110, Taiwan.
Department of Statistics, Faculty of Science and Technology, Universitas PGRI Adi Buana, Surabaya 60234, Indonesia.

Phan Vu Thuy Dung (PVT)

Graduate Institute of Cancer Biology and Drug Discovery, College of Medical Science and Technology, Taipei Medical University, Taipei 110, Taiwan.

Do Thi Minh Xuan (DTM)

Graduate Institute of Cancer Biology and Drug Discovery, College of Medical Science and Technology, Taipei Medical University, Taipei 110, Taiwan.

Sanskriti Dey (S)

Graduate Institute of Cancer Biology and Drug Discovery, College of Medical Science and Technology, Taipei Medical University, Taipei 110, Taiwan.

Chih-Yang Wang (CY)

Graduate Institute of Cancer Biology and Drug Discovery, College of Medical Science and Technology, Taipei Medical University, Taipei 110, Taiwan.
Ph.D. Program for Cancer Molecular Biology and Drug Discovery, College of Medical Science and Technology, Taipei Medical University and Academia Sinica, Taipei 110, Taiwan.

Yen-Nien Liu (YN)

Graduate Institute of Cancer Biology and Drug Discovery, College of Medical Science and Technology, Taipei Medical University, Taipei 110, Taiwan.
Ph.D. Program for Cancer Molecular Biology and Drug Discovery, College of Medical Science and Technology, Taipei Medical University and Academia Sinica, Taipei 110, Taiwan.
TMU Research Center of Cancer Translational Medicine, Taipei Medical University, Taipei 110, Taiwan.

Classifications MeSH